Cornerstone Pharmaceuticals Adds New Clinical Trial Site for a Evaluation of Its First-in-Class Anti-Cancer Agent …
Cornerstone Pharmaceuticals Adds New Clinical Trial Site for a Evaluation of Its First-in-Class Anti-Cancer Agent …
Cornerstone Pharmaceuticals, Inc. currently voiced a further of Mary Crowley Cancer Research Centers to a register of sites for a ongoing Phase I/II clinical trials of a first-in-class anti-cancer agent, CPI-613. Â Cornerstone is a personality in a find as well as growth of cancer therapies which gain on as well as interrupt a singular metabolic processes of cancer cells.